Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
798
mi
from 43215
Alexandria, LA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
798
mi
from 43215
Alexandria, LA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
699
mi
from 43215
Scarborough, ME
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
699
mi
from 43215
Scarborough, ME
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
206
mi
from 43215
Lansing, MI
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
206
mi
from 43215
Lansing, MI
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Hartford Hospital- The Institute of Living
554
mi
from 43215
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Hartford Hospital- The Institute of Living
554
mi
from 43215
Hartford, CT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
629
mi
from 43215
Nashua, NH
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
629
mi
from 43215
Nashua, NH
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
2027
mi
from 43215
Portland, OR
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2027
mi
from 43215
Portland, OR
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
New York Methodist Hospital
478
mi
from 43215
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
478
mi
from 43215
Brooklyn, NY
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Cotton-O'Neil Cancer Center
678
mi
from 43215
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Cotton-O'Neil Cancer Center
678
mi
from 43215
Topeka, KA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
A Study in Patients With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)
Status: Archived
UMDNJ-Robert Wood Johnson Medical Center
453
mi
from 43215
New Brunswick, NJ
Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)
Status: Archived
Updated: 1/1/1970
UMDNJ-Robert Wood Johnson Medical Center
453
mi
from 43215
New Brunswick, NJ
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment.
The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents
Status: Archived
Walter Reed Army Medical Center
329
mi
from 43215
Washington,
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment.
The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents
Status: Archived
Updated: 1/1/1970
Walter Reed Army Medical Center
329
mi
from 43215
Washington,
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment.
The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents
Status: Archived
MedStar Research Institute
330
mi
from 43215
Washington,
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment.
The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents
Status: Archived
Updated: 1/1/1970
MedStar Research Institute
330
mi
from 43215
Washington,
A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians
A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians
Status: Archived
Emory University
435
mi
from 43215
Atlanta, GA
A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians
A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians
Status: Archived
Updated: 1/1/1970
Emory University
435
mi
from 43215
Atlanta, GA
Biomarkers of Metabolic Syndrome and Prediabetes
Assessing Salivary Biomarkers for Risk Stratification in Metabolic Syndrome
Status: Archived
West Virginia School of Osteopathic Medicine
203
mi
from 43215
Lewisburg, WV
Biomarkers of Metabolic Syndrome and Prediabetes
Assessing Salivary Biomarkers for Risk Stratification in Metabolic Syndrome
Status: Archived
Updated: 1/1/1970
West Virginia School of Osteopathic Medicine
203
mi
from 43215
Lewisburg, WV
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10007 Boehringer Ingelheim Investigational Site
1949
mi
from 43215
Chula Vista, CA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10007 Boehringer Ingelheim Investigational Site
1949
mi
from 43215
Chula Vista, CA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10018 Boehringer Ingelheim Investigational Site
977
mi
from 43215
Pembroke Pines, FL
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10018 Boehringer Ingelheim Investigational Site
977
mi
from 43215
Pembroke Pines, FL
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10016 Boehringer Ingelheim Investigational Site
433
mi
from 43215
Decatur, GA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10016 Boehringer Ingelheim Investigational Site
433
mi
from 43215
Decatur, GA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10015 Boehringer Ingelheim Investigational Site
1715
mi
from 43215
Boise, ID
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10015 Boehringer Ingelheim Investigational Site
1715
mi
from 43215
Boise, ID
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
274
mi
from 43215
Chicago, IL
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
274
mi
from 43215
Chicago, IL
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10012 Boehringer Ingelheim Investigational Site
343
mi
from 43215
Towson, MD
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10012 Boehringer Ingelheim Investigational Site
343
mi
from 43215
Towson, MD
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10004 Boehringer Ingelheim Investigational Site
213
mi
from 43215
Flint, MI
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10004 Boehringer Ingelheim Investigational Site
213
mi
from 43215
Flint, MI
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1199.14.1072 Boehringer Ingelheim Investigational Site
618
mi
from 43215
Kansas City, MO
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1199.14.1072 Boehringer Ingelheim Investigational Site
618
mi
from 43215
Kansas City, MO
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10003 Boehringer Ingelheim Investigational Site
482
mi
from 43215
Bronx, NY
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10003 Boehringer Ingelheim Investigational Site
482
mi
from 43215
Bronx, NY
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
416
mi
from 43215
Philadelphia, PA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
416
mi
from 43215
Philadelphia, PA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
162
mi
from 43215
Pittsburgh, PA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
162
mi
from 43215
Pittsburgh, PA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10009 Boehringer Ingelheim Investigational Site
927
mi
from 43215
Arlington, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10009 Boehringer Ingelheim Investigational Site
927
mi
from 43215
Arlington, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
911
mi
from 43215
Dallas, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
911
mi
from 43215
Dallas, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
991
mi
from 43215
Houston, TX
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
1218.64.10010 Boehringer Ingelheim Investigational Site
2012
mi
from 43215
Tacoma, WA
Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control
Status: Archived
Updated: 1/1/1970
1218.64.10010 Boehringer Ingelheim Investigational Site
2012
mi
from 43215
Tacoma, WA
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease
Status: Archived
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
343
mi
from 43215
Baltimore, MD
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Clinical Pharmacology of Miami
984
mi
from 43215
Miami, FL
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Pharmacology of Miami
984
mi
from 43215
Miami, FL
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
ICON Development Solutions
1133
mi
from 43215
San Antonio, TX
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
ICON Development Solutions
1133
mi
from 43215
San Antonio, TX
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
358
mi
from 43215
Rochester, NY
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
358
mi
from 43215
Rochester, NY
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
659
mi
from 43215
Fayetteville, AR
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
659
mi
from 43215
Fayetteville, AR
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
1982
mi
from 43215
Los Angeles, CA
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
1982
mi
from 43215
Los Angeles, CA
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
297
mi
from 43215
Bloomingdale, IL
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
297
mi
from 43215
Bloomingdale, IL
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Darien Pediatric Associates
506
mi
from 43215
Darien, CT
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
506
mi
from 43215
Darien, CT
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
740
mi
from 43215
Biloxi, MS
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
740
mi
from 43215
Biloxi, MS
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
837
mi
from 43215
Fargo, ND
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
837
mi
from 43215
Fargo, ND
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
106
mi
from 43215
Akron, OH
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
106
mi
from 43215
Akron, OH
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Pfizer Investigational Site
995
mi
from 43215
Houston, TX
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And Hypertension
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
995
mi
from 43215
Houston, TX